GuideWell Mutual, Blue Shield California and existing backer Premera Blue Cross all invested in the healthcare prediction platform developer.

Merck & Co and Lilly Asia Ventures will exit the biotherapeutics technology developer in an acquisition by Evotec that will be sized at up to $90m.

Eli Lilly, WuXi Biologics and Alexandria-backed cancer and orphan disease therapy developer Inhibrx has received $40m in funding from Viking Global Investors.

MassMutual Ventures co-led the healthcare data platform developer's series B round, which also featured Aviva Ventures and Jianke.

William Taranto spoke about his near decade at Merck Global Health Innovation Fund and how corporate venturing has evolved in that time.

Medtronic, LivaNova and Baxter Healthcare have helped commit $53.5m for the third medical device-based fund to be raised under the MD Start moniker.

Alphabet, Novartis and Johnson & Johnson have contributed to a series C round for Cala Health, which is preparing to release its wearable hand-tremor treatment device.

Susquehanna International Group has led a series B round for elderly healthcare services provider Shanzhen that was in the eight-figure dollar range.

The drug development software provider has added $25m to an Alphabet and Wuxi AppTech-backed first tranche it closed in January.

Lundbeckfond Ventures contributed to a round that will fund clinical trials for Reneo Pharmaceuticals' mitochondrial disease therapies.